Publications by authors named "Irene Garcia Megias"
Assessment of the therapeutic efficacy of [Lu]Lu-PSMA-X compared to taxane chemotherapy in taxane-chemo-naïve patients with metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Eur J Nucl Med Mol Imaging
October 2024
Article Synopsis
- Radioligand therapy (RLT) with Lu-labelled prostate specific membrane antigen ([Lu]Lu-PSMA-X) is showing promise as a treatment for metastatic castration-resistant prostate cancer (mCRPC), especially for those who haven't received taxane chemotherapy.
- This study conducted a systematic review and meta-analysis to compare the efficacy of [Lu]Lu-PSMA-X to traditional taxane chemotherapy in patients who haven't been treated with taxane.
- The results indicated that both treatment groups had similar rates of prostate specific antigen (PSA) response, suggesting that [Lu]Lu-PSMA-X could be a viable option for mCRPC patients who are taxane-naïve.
Article Synopsis
- Prostate cancer is a complicated health issue that requires careful diagnosis and treatment.
- Radioligand therapy using special agents has shown to be helpful for some patients with prostate cancer.
- The review examines how to treat prostate cancer based on the latest guidelines and highlights the benefits of this therapy.
Multitracer PET/CT with [F]Fluorodeoxiglucose and [F]Fluorocholine in the Initial Staging of Multiple Myeloma Patients Applying the IMPeTus Criteria: A Pilot Study.
Diagnostics (Basel)
April 2023
Initial staging of patients diagnosed with multiple myeloma (MM) can lead to negative results using conventional diagnostic imaging workup, including [F]Fluorodesoxiglucose ([F]FDG) PET/CT. The aim of this prospective pilot study was to evaluate the diagnostic efficacy of [F]Fluorocholine ([F]FCH) PET/CT in the initial staging of MM patients who were candidates for autologous bone marrow transplant. : The inclusion criteria of our study were: (a) patients diagnosed with MM; (b) candidates for autologous bone marrow transplant (AT); and (c) studied with [F]FCH PET/CT and [F]FDG PET/CT for initial staging less than 4 weeks apart.
View Article and Find Full Text PDFImmunotherapy is based on manipulation of the immune system in order to act against tumour cells, with growing evidence especially in melanoma patients. The challenges faced by this new therapeutic tool are (i) finding valid evaluation criteria for response assessment; (ii) knowing and distinguishing between "atypical" response patterns; (iii) using PET biomarkers as predictive and response evaluation parameters and (iv) diagnosis and management of immunorelated adverse effects. This review is focused on melanoma patients analysing (a) the role of [F]FDG PET/CT in the mentioned challenges; (b) the evidence of its efficacy.
View Article and Find Full Text PDF